The Medical Device Manufacturers Association (MDMA) and the Alliance of U.S. Startups and Inventors for Jobs (USIJ) sent a letter today to the leadership of the Senate Judiciary Committee and the Judiciary Committee’s Subcommittee on Intellectual Property to express their support for both the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) and the Patent Eligibility Restoration Act (PERA). Both PREVAIL and PERA were introduced on June 22, 2023. The PREVAIL Act aims to reform Patent Trial and Appeal Board (PTAB) practices while PERA would eliminate all judicially-created exceptions to U.S. patent eligibility law.
Recent Posts
- Squires’ Responses to Senate Judiciary Committee Focus on Balance, Backlog and ‘Born Strong’ Patents
- USPTO Study into Applications with Large Patent Families Raises Questions
- Agency’s Acting Deputy Director Says It’s Back to Basics for the USPTO
- Quantum Computers and the Evolution of AI | IPWatchdog Unleashed
- Second C4IP Congressional Scorecard Finds Pro-Innovation Efforts Lacking Among Most DC Lawmakers